Literature DB >> 10067706

A study of human rabies immune globulin manufactured by the Thai Red Cross.

A Chantanakajornfung1, N Naraporn, W Khumphai, M Bejavongkulchai, C Mitmoonpitak, H Wilde.   

Abstract

This is a prospective post marketing study of 4496 patients presenting with severe animal bites in a canine rabies endemic region. They received human rabies immune globulin manufactured from volunteer blood donors at the National Blood Center of the Thai Red Cross Society at Bangkok. All patients also received a full course of tissue culture rabies vaccine. Only three subjects reported an adverse reaction (redness and itching at the immune globulin injection sites). None of the patients died during the subsequent 18 month follow up period.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067706     DOI: 10.1016/s0264-410x(98)00314-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.

Authors:  Yunlong Qin; Christina Hutson; Xianfu Wu; Jingyao Xu; Darin Carroll
Journal:  Enliven J Stem Cell Res Regen Med       Date:  2016-07-06

2.  Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab).

Authors:  Beatriz P Quiambao; Hazel Z Dytioco; Ruby M Dizon; Marilyn E Crisostomo; Thelma M Laot; Dirk E Teuwen
Journal:  PLoS Negl Trop Dis       Date:  2008-05-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.